Navigation Links
Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
Date:9/25/2007

phorylase, or TP, Xeloda is transformed into 5-FU, a cytotoxic (cell-killing) drug. Because many cancers have higher levels of TP than does normal tissue, more 5-FU is delivered to the tumor than to other tissue.

Conventional, approved Xeloda dosing on a 14-on/7-off schedule is 1250 mg/m(2) twice daily (total of 2500 mg/m(2)/day).

A clinically important drug interaction between Xeloda and warfarin has been demonstrated; altered coagulation parameters and/or bleeding and death have been reported. Clinically significant increases in prothrombin time (PT) and INR have been observed within days to months after starting Xeloda, and infrequently within one month of stopping Xeloda.

For patients receiving both drugs concomitantly, frequent monitoring of INR or PT is recommended. Age greater than 60 and a diagnosis of cancer independently predispose patients to an increased risk of coagulopathy.

Xeloda is contraindicated in patients who have a known hypersensitivity to 5-fluorouracil, and in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. Xeloda is contraindicated in patients with severe renal impairment. For patients with moderate renal impairment, dose reduction is required.

The most common adverse events (greater than or equal to 20%) of Xeloda monotherapy were diarrhea, nausea, stomatitis and hand-foot syndrome. As with any cancer therapy, there is a risk of side effects, and these are usually manageable and reversible with dose modification or interruption.

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche has been committed to developing innovative products and services that address prevention, diagnosis and treatment of diseases, thus enhancing people's health and qua
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014  Air Products (NYSE: ... medical oxygen is vital to any healthcare facility. This ... not only improve the efficiency of its oxygen supply ... highlight these systems—including systems for emergency oxygen supply ... August 4-5 at the 51 st ASHE ...
(Date:7/28/2014)... 28, 2014 Southern Research Institute today ... President and CEO of Southern Research Institute, has ... (CRS) for the 2014-2015 term.  The inauguration took ... 12 in Chicago with ... The Controlled Release Society is an international, ...
(Date:7/28/2014)... WELLINGTON, New Zealand , July 28, 2014 ... Institute in Sweden has ... across multiple vendor platforms and has associated volumetrically ... Published in Cancer Epidemiology, Biomarkers & Prevention ... volumetric mammographic density: a tool for widespread breast ...
Breaking Medicine Technology:Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 2Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 3Arthur J. Tipton, Ph.D., Named President of Controlled Release Society 2Arthur J. Tipton, Ph.D., Named President of Controlled Release Society 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 4
... Cardinal Health today announced its board of directors has approved a ... will join the company,s board of directors. At ... per share, payable on Oct. 15 to shareholders of record on ... for Cardinal Health. The board of directors also ...
... The National Pharmaceutical Council (NPC) today welcomed global specialty ... Jeffrey M. Jonas, senior vice president, specialty pharma R&D, ... of directors. "The last few years ... has left many important questions unresolved.  For the pharmaceutical ...
Cached Medicine Technology:Cardinal Health Board of Directors Approves Cash Dividend, Elects David P. King as Director 2Cardinal Health Board of Directors Approves Cash Dividend, Elects David P. King as Director 3National Pharmaceutical Council Welcomes Shire as Its Newest Member 2
(Date:7/28/2014)... A lush green lawn offers the perfect setting for backyard ... heat, lack of rain, foot traffic, and insects can often ... Grounds Guys recommends these suggestions for nurturing your summer lawn: ... and set the height on the lawn mower about one ... heat and allows roots to retain water and grow more ...
(Date:7/28/2014)... 28, 2014 UHY LLP, a member ... edition of UHY International Business – Issue 29. This ... on the most current business challenges and key issues ... 29 covers the following topics:, , ... will thrive over the next five years? Where are ...
(Date:7/28/2014)... July 28, 2014 Dawn Echols’ ... sales, finance, and music. This experience has honed ... direction of psychology. Her professional counseling ( http://dawningphoenix.com ... court-ordered treatment for offenders in domestic violence. ... Phoenix, LLC, she enjoys counseling individuals and groups ...
(Date:7/28/2014)... version of a surgical procedure to treat severe chronic ... 90 percent of the time in patients treated at ... Division of Plastic and Reconstructive Surgery report that more ... procedure all of whom had headaches associated with ... a year later. The team,s paper has received ...
(Date:7/28/2014)... 28, 2014 Shofner Vision Center ... June . Renowned LASIK and Cataract Surgeon, Dr. ... significant funds and public awareness for local not-for-profit ... personnel and their families. “This was our 2nd ... nearly $5,000 to a variety of local not-for-profit ...
Breaking Medicine News(10 mins):Health News:Nurturing Lawns in the Summer Heat: The Grounds Guys® Offers Tips on Caring for Lawns This Summer 2Health News:Uhy International Business Issue 29 Now Available 2Health News:Uhy International Business Issue 29 Now Available 3Health News:Dawn M. Echols, M.S., LPC of Dawning Phoenix Speaks at Newly Formed Task Force 2Health News:Non-endoscopic migraine surgery provides significant symptom relief 2Health News:Shofner Vision Center’s “Operation Military June” Provided Funds For Local Not-For-Profit Organizations Supporting Military And Their Families 2Health News:Shofner Vision Center’s “Operation Military June” Provided Funds For Local Not-For-Profit Organizations Supporting Military And Their Families 3
... Archives of Internal Medicine says that drinking two cups of ... 46 percent. // ,Researchers from the Karolinska ... of 40 and 76 during 1987 to 2004. They found ... this time. When the study started two-thirds of the participants ...
... good sleep help elderly women maintain a destructive protein ... is connected to health problems like Alzheimer's, heart disease, ... Interleukin-6 (IL-6) which runs in the blood stream rises ... damaging protein sank in women who managed to sleep ...
... and amoxicillin when it comes to treating ailments like ... effective. Doctors, who reviewed the treatment given to // ... the newer drugs is more effective than the traditional ... ,Pediatricians at the University of Rochester Medical Center found ...
... studied the blood pressure (BP) and eating habits of 4,304 people ... 18 years and 30 years. An inverse connection was // seen ... grain, and milk, when in comparison to low plant food intake. ... and 36% by the consumption of the second and fifth quintiles. ...
... Canada has announced a ban on the anti-inflammatory drug Bextra, ... from the drug were outweighed by the cardiovascular risks, including ... to an expert safety panel. ,The drug ... even prove to be fatal. Pfizer had earlier withdrawn the ...
... is under threat from a drinking problem. This result is ... for Addictions Research of B.C. compared drinking patterns of the ... on the Canadian Addiction Survey done in 2004. ,The ... guidelines for alcohol consumption and 53 per cent were above ...
Cached Medicine News:Health News:Penicillin To Pave Way For New Antibiotics 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: